University Of Minnesota
Minneapolis, Minnesota, 55455, United States
Location status: Recruiting
NCT Number: NCT05557864
This protocol will characterize the effects of deep brain stimulation (DBS) location (both adverse and beneficial) on motor signs in people with Parkinson's disease (PD). This information can be used to inform future DBS protocols to tailor stimulation to the specific needs of a patient. If targeted dorsal GP stimulation is shown to significantly improve motor features that are typically resistant to dopamine replacement therapy, these experiments will likely have major impact on clinical practice by providing a potential strategy to these medically intractable symptoms.
Interested in participating?
Request Info21 year–89 year
All sexes
Interventional
Not applicable
Minneapolis, Minnesota, 55455, United States
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Pallidal Deep Brain Stimulation
Time frame: 3 weeks
Average movement rate and amplitude for each tone rate-movement amplitude interval. The amount of variability in angular displacement and velocity will be calculated using the root mean square of the zero mean signal. The structure of the variability will be calculated using the sample entropy function. In addition, we will quantify the number and duration of movement festination or freezing episodes.
Contact information is provided by the study sponsor or research team.
University of Minnesota
Other
Effects of Pallidal Deep Brain Stimulation Location on Motor Impairment in Parkinson's Disease; Udall Project 2 Aims 1 & 2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07442747
Basal Ganglia Diseases, Behavior
Cleveland, Ohio, United States
View Trial DetailsNCT07330258
Basal Ganglia Diseases, Brain Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT04799470
Basal Ganglia Diseases, Brain Diseases
Omaha, Nebraska, United States
View Trial DetailsNCT02119611
Basal Ganglia Diseases, Brain Diseases
Bethesda, Maryland, United States
View Trial Details